Clinical Cancer Research: 21 (19)

Highlights

Highlights

Highlights of This Issue

Clin Cancer Res October 1 2015 21 (19) 4245-4245;

Editorial

Editorial | Free Article

AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine

Kenneth C. Anderson

Clin Cancer Res October 1 2015 21 (19) 4247-4247; DOI:10.1158/1078-0432.CCR-15-1978

CCR 20th Anniversary Commentary

CCR 20th Anniversary Commentary | Free Article

CCR 20^th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma—The Progress and the Limitations

Nataliya Mar, Annick Desjardins and James J. Vredenburgh

Clin Cancer Res October 1 2015 21 (19) 4248-4250; DOI:10.1158/1078-0432.CCR-15-1381

CCR Translations

CCR Translations

Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!

Andrea van Elsas, Hans van Eenennaam and John B. Haanen

Clin Cancer Res October 1 2015 21 (19) 4251-4253; DOI:10.1158/1078-0432.CCR-15-1126
CCR Translations

Next Generation of Preclinical Liver Cancer Models

Achim Weber, Tracy O'Connor and Mathias Heikenwalder

Clin Cancer Res October 1 2015 21 (19) 4254-4256; DOI:10.1158/1078-0432.CCR-15-1152

CCR Perspectives in Drug Approval

CCR Perspectives in Drug Approval

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Geoffrey Kim, Gwynn Ison, Amy E. McKee, Hui Zhang, Shenghui Tang, Thomas Gwise, Rajeshwari Sridhara, Eunice Lee, Abraham Tzou, Reena Philip, Haw-Jyh Chiu, Tiffany K. Ricks, Todd Palmby, Anne Marie Russell, Gaetan Ladouceur, Elimika Pfuma, Hongshan Li, Liang Zhao, Qi Liu, Rajesh Venugopal, Amna Ibrahim and Richard Pazdur

Clin Cancer Res October 1 2015 21 (19) 4257-4261; DOI:10.1158/1078-0432.CCR-15-0887

CCR Drug Updates

CCR Drug Updates

Blinatumomab for the Treatment of Philadelphia Chromosome–Negative, Precursor B-cell Acute Lymphoblastic Leukemia

Ofir Wolach and Richard M. Stone

Clin Cancer Res October 1 2015 21 (19) 4262-4269; DOI:10.1158/1078-0432.CCR-15-0125

Molecular Pathways

Molecular Pathways

Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

Wade T. Iams and Christine M. Lovly

Clin Cancer Res October 1 2015 21 (19) 4270-4277; DOI:10.1158/1078-0432.CCR-14-2518
Molecular Pathways

Molecular Pathways: Targeting the CXCR4–CXCL12 Axis—Untapped Potential in the Tumor Microenvironment

Stefania Scala

Clin Cancer Res October 1 2015 21 (19) 4278-4285; DOI:10.1158/1078-0432.CCR-14-0914

Cancer Therapy: Clinical

Cancer Therapy: Clinical | AuthorChoice

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, S. Peter Kang, Drew Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss-Schaap, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, Guillermo Espino, Kevin Gergich, Liliana Delgado, Adil Daud, Jill A. Lindia, Xiaoyun Nicole Li, Robert H. Pierce, Jennifer H. Yearley, Dianna Wu, Omar Laterza, Manfred Lehnert, Robert Iannone and Anthony W. Tolcher

Clin Cancer Res October 1 2015 21 (19) 4286-4293; DOI:10.1158/1078-0432.CCR-14-2607
Cancer Therapy: Clinical | AuthorChoice

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease

Corey Casper, Shalini Chaturvedi, Nikhil Munshi, Raymond Wong, Ming Qi, Michael Schaffer, Rajesh Bandekar, Brett Hall, Helgi van de Velde, Jessica Vermeulen, Manjula Reddy and Frits van Rhee

Clin Cancer Res October 1 2015 21 (19) 4294-4304; DOI:10.1158/1078-0432.CCR-15-0134
Cancer Therapy: Clinical

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen Jr, Lea Krekow, Frankie Ann Holmes, Svetislava Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert Brooks, Kristi McIntyre, Carrie Brownstein, Silke Hoersch, Joanne L. Blum and Stephen Jones

Clin Cancer Res October 1 2015 21 (19) 4305-4311; DOI:10.1158/1078-0432.CCR-15-0636
Cancer Therapy: Clinical

High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses

Miriam E. Mossoba, David C. Halverson, Roger Kurlander, Bazetta Blacklock Schuver, Ashley Carpenter, Brenna Hansen, Seth M. Steinberg, Syed Abbas Ali, Nishant Tageja, Frances T. Hakim, Juan Gea-Banacloche, Claude Sportes, Nancy M. Hardy, Dennis D. Hickstein, Steven Z. Pavletic, Hanh Khuu, Marianna Sabatini, David Stroncek, Bruce L. Levine, Carl H. June, Jacopo Mariotti, Olivier Rixe, Antonio Tito Fojo, Michael R. Bishop, Ronald E. Gress and Daniel H. Fowler

Clin Cancer Res October 1 2015 21 (19) 4312-4320; DOI:10.1158/1078-0432.CCR-15-0340
Cancer Therapy: Clinical

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib

Primo N. Lara Jr, Jeff Longmate, Philip C. Mack, Karen Kelly, Mark A. Socinski, Ravi Salgia, Barbara Gitlitz, Tianhong Li, Mariana Koczywas, Karen L. Reckamp and David R. Gandara

Clin Cancer Res October 1 2015 21 (19) 4321-4326; DOI:10.1158/1078-0432.CCR-14-3281
Cancer Therapy: Clinical

Phase Ia Study of FoxP3⁺ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

Koji Kurose, Yoshihiro Ohue, Hisashi Wada, Shinsuke Iida, Takashi Ishida, Takashi Kojima, Toshihiko Doi, Susumu Suzuki, Midori Isobe, Takeru Funakoshi, Kazuhiro Kakimi, Hiroyoshi Nishikawa, Heiichiro Udono, Mikio Oka, Ryuzo Ueda and Eiichi Nakayama

Clin Cancer Res October 1 2015 21 (19) 4327-4336; DOI:10.1158/1078-0432.CCR-15-0357

Personalized Medicine and Imaging

Personalized Medicine and Imaging

Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy

Masaaki Komatsu, Heather E. Wheeler, Suyoun Chung, Siew-Kee Low, Claudia Wing, Shannon M. Delaney, Lidija K. Gorsic, Atsushi Takahashi, Michiaki Kubo, Deanna L. Kroetz, Wei Zhang, Yusuke Nakamura and M. Eileen Dolan

Clin Cancer Res October 1 2015 21 (19) 4337-4346; DOI:10.1158/1078-0432.CCR-15-0133
Personalized Medicine and Imaging | AuthorChoice

Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions

Andrew J. Radosevich, Nikhil N. Mutyal, Adam Eshein, The-Quyen Nguyen, Bradley Gould, Jeremy D. Rogers, Michael J. Goldberg, Laura K. Bianchi, Eugene F. Yen, Vani Konda, Douglas K. Rex, Jacques Van Dam, Vadim Backman and Hemant K. Roy

Clin Cancer Res October 1 2015 21 (19) 4347-4355; DOI:10.1158/1078-0432.CCR-15-0136
Personalized Medicine and Imaging

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers

Friederike Göke, Alina Franzen, Trista K. Hinz, Lindsay A. Marek, Petros Yoon, Rakesh Sharma, Maike Bode, Anne von Maessenhausen, Brigitte Lankat-Buttgereit, Antonia Göke, Carsten Golletz, Robert Kirsten, Diana Boehm, Wenzel Vogel, Emily K. Kleczko, Justin R. Eagles, Fred R. Hirsch, Tobias Van Bremen, Friedrich Bootz, Andreas Schroeck, Jihye Kim, Aik-Choon Tan, Antonio Jimeno, Lynn E. Heasley and Sven Perner

Clin Cancer Res October 1 2015 21 (19) 4356-4364; DOI:10.1158/1078-0432.CCR-14-3357
Personalized Medicine and Imaging

Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer

Hua Yuan, Jiuan Chen, Yiqiang Liu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin and Yuntao Xie

Clin Cancer Res October 1 2015 21 (19) 4365-4372; DOI:10.1158/1078-0432.CCR-14-3354
Personalized Medicine and Imaging

Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T₂ Maps Derived from Dual-Echo Turbo Spin-Echo MRI

Benjamin M. Ellingson, Albert Lai, Huytram N. Nguyen, Phioanh L. Nghiemphu, Whitney B. Pope and Timothy F. Cloughesy

Clin Cancer Res October 1 2015 21 (19) 4373-4383; DOI:10.1158/1078-0432.CCR-14-2862
Personalized Medicine and Imaging

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma

Elena Zamagni, Cristina Nanni, Katia Mancuso, Paola Tacchetti, Annalisa Pezzi, Lucia Pantani, Beatrice Zannetti, Ilaria Rambaldi, Annamaria Brioli, Serena Rocchi, Carolina Terragna, Marina Martello, Giulia Marzocchi, Enrica Borsi, Ilaria Rizzello, Stefano Fanti and Michele Cavo

Clin Cancer Res October 1 2015 21 (19) 4384-4390; DOI:10.1158/1078-0432.CCR-15-0396

Cancer Therapy: Preclinical

Cancer Therapy: Preclinical

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma

Matthew J. Barth, Cory Mavis, Myron S. Czuczman and Francisco J. Hernandez-Ilizaliturri

Clin Cancer Res October 1 2015 21 (19) 4391-4397; DOI:10.1158/1078-0432.CCR-15-0056
Cancer Therapy: Preclinical

β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer

Coral San Millán, Beatriz Soldevilla, Paloma Martín, Beatriz Gil-Calderón, Marta Compte, Belén Pérez-Sacristán, Encarnación Donoso, Cristina Peña, Jesús Romero, Fernando Granado-Lorencio, Félix Bonilla and Gemma Domínguez

Clin Cancer Res October 1 2015 21 (19) 4398-4409; DOI:10.1158/1078-0432.CCR-14-2027
Cancer Therapy: Preclinical

Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle

Erik C. Dreaden, Yi Wen Kong, Stephen W. Morton, Santiago Correa, Ki Young Choi, Kevin E. Shopsowitz, Kasper Renggli, Ronny Drapkin, Michael B. Yaffe and Paula T. Hammond

Clin Cancer Res October 1 2015 21 (19) 4410-4419; DOI:10.1158/1078-0432.CCR-15-0013
Cancer Therapy: Preclinical

Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence

Pinbo Huang, Baoxiong Zhuang, Heyun Zhang, Haiyan Yan, Zhiyu Xiao, Wenbin Li, Jianlong Zhang, Qibin Tang, Kaishun Hu, H. Phillip Koeffler, Jie Wang and Dong Yin

Clin Cancer Res October 1 2015 21 (19) 4420-4430; DOI:10.1158/1078-0432.CCR-14-2067
Cancer Therapy: Preclinical

Targeting of HPV-16⁺ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6

Lindsey M. Draper, Mei Li M. Kwong, Alena Gros, Sanja Stevanović, Eric Tran, Sid Kerkar, Mark Raffeld, Steven A. Rosenberg and Christian S. Hinrichs

Clin Cancer Res October 1 2015 21 (19) 4431-4439; DOI:10.1158/1078-0432.CCR-14-3341
Cancer Therapy: Preclinical

Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib

Claudia Groß, Katja Steiger, Sufyan Sayyed, Irina Heid, Annette Feuchtinger, Axel Walch, Julia Heß, Kristian Unger, Horst Zitzelsberger, Marcus Settles, Anna Melissa Schlitter, Juliane Dworniczak, Jennifer Altomonte, Oliver Ebert, Markus Schwaiger, Ernst Rummeny, Andreas Steingötter, Irene Esposito and Rickmer Braren

Clin Cancer Res October 1 2015 21 (19) 4440-4450; DOI:10.1158/1078-0432.CCR-14-2018

Biology of Human Tumors

Biology of Human Tumors

Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis

Joakim Crona, Samuel Backman, Rajani Maharjan, Markus Mayrhofer, Peter Stålberg, Anders Isaksson, Per Hellman and Peyman Björklund

Clin Cancer Res October 1 2015 21 (19) 4451-4460; DOI:10.1158/1078-0432.CCR-14-2854
Biology of Human Tumors

Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity

Tae-Min Kim, Seung-Hyun Jung, Chang Hyeok An, Sung Hak Lee, In-Pyo Baek, Min Sung Kim, Sung-Won Park, Je-Keun Rhee, Sug-Hyung Lee and Yeun-Jun Chung

Clin Cancer Res October 1 2015 21 (19) 4461-4472; DOI:10.1158/1078-0432.CCR-14-2413
Biology of Human Tumors

New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice

John B. Kisiel, Massimo Raimondo, William R. Taylor, Tracy C. Yab, Douglas W. Mahoney, Zhifu Sun, Sumit Middha, Saurabh Baheti, Hongzhi Zou, Thomas C. Smyrk, Lisa A. Boardman, Gloria M. Petersen and David A. Ahlquist

Clin Cancer Res October 1 2015 21 (19) 4473-4481; DOI:10.1158/1078-0432.CCR-14-2469
Biology of Human Tumors

Tissue Transglutaminase Mediated Tumor–Stroma Interaction Promotes Pancreatic Cancer Progression

Jiyoon Lee, Salvatore Condello, Bakhtiyor Yakubov, Robert Emerson, Andrea Caperell-Grant, Kiyotaka Hitomi, Jingwu Xie and Daniela Matei

Clin Cancer Res October 1 2015 21 (19) 4482-4493; DOI:10.1158/1078-0432.CCR-15-0226

Letter to the Editor

Letter to the Editor

Ancient Retrovirus Targeted by Engineered T Cells in Melanoma—Letter

John M. Grange and Bernd Krone

Clin Cancer Res October 1 2015 21 (19) 4494-4494; DOI:10.1158/1078-0432.CCR-15-1548

Corrections

Corrections

Correction: Pancreatic Cancer-Derived Exosomes Causes Paraneoplastic β-cell Dysfunction

Clin Cancer Res October 1 2015 21 (19) 4495-4495; DOI:10.1158/1078-0432.CCR-15-1524
Corrections

Correction: The Prostate Cancer Susceptibility Variant rs2735839 Near KLK3 Gene Is Associated with Aggressive Prostate Cancer and Can Stratify Gleason Score 7 Patients

Clin Cancer Res October 1 2015 21 (19) 4496-4496; DOI:10.1158/1078-0432.CCR-15-1935

Main menu

User menu

Search

Table of Contents

Highlights

Editorial

CCR 20th Anniversary Commentary

CCR Translations

CCR Perspectives in Drug Approval

CCR Drug Updates

Molecular Pathways

Cancer Therapy: Clinical

Personalized Medicine and Imaging

Cancer Therapy: Preclinical

Biology of Human Tumors

Letter to the Editor

Corrections

Issue Highlights

Jump to

Articles

Info for

About Clinical Cancer Research